Risk Analysis and Essential Principles in Thailand Registration Dossiers

1. Key takeaways

Thailand reviews risk management documentation as part of registration. In the CSDT dossier for Class 2-4 devices, the risk analysis and the Essential Principles, meaning the Essential Safety and Performance Principles, are two parallel core modules. The former corresponds to the ISO 14971 framework, and the latter corresponds to the ASEAN list of Essential Safety and Performance Principles. The two documents are complementary rather than duplicated: the risk analysis works from the bottom up, starting from the specific hazards of the product, while the Essential Principles work from the top down, answering the regulator’s principle list item by item, and their conclusions must agree with each other. Because both modules draw on the same underlying design and verification work, preparing them together, against one shared evidence base, is materially cheaper and safer than preparing them separately at different points in the project.

• Answer the Essential Principles item by item with an evidence index for each entry; a blanket statement that the product conforms to the ASEAN Essential Principles is the most common mistake among Chinese manufacturers.
• Entries that do not apply must be answered with N/A plus a justification, never left blank.
• The risk analysis must be product-specific, covering the actual hazards of the device: energy hazards, biological hazards, environmental hazards, use errors, software failures, and the like, rather than a generic template.
• The risk analysis must close the loop through five steps: identification, evaluation, control measures, verification of control effectiveness, and the acceptability determination for residual risk; all five are required.
• Control measures claimed in the risk analysis must have corresponding evidence in test reports, IFU warnings, and label warnings.
• The Abridged route exempts the verification and validation summary and the risk analysis, in exchange for the intended use statement, the marketing history statement, the safety statement, and proof of reference authority approval.

2. Legal basis

The requirements rest on the Thai FDA website Class 2-4 document list matrix, under which the Risk Analysis and the Essential Principles are mandatory items on the Full route, while the Abridged route exempts the Risk Analysis. The Essential Principles module follows the ASEAN CSDT list of Essential Safety and Performance Principles, and the risk analysis follows the ISO 14971 risk management standard. Under the matrix, the Abridged route requires in compensation the intended use statement, the marketing history statement, the safety statement, and proof of approval by the reference authority; the design exchanges a documented marketing history and safety record for exemptions from parts of the technical file. The Reliance route exemption of expert review was established by the Thai FDA announcement of 2024-06-04, issued in B.E. 2567. The essential structure of an acceptable Essential Principles response is an item-by-item table of the following kind, which also shows how evidence is indexed to the dossier.

3. Expert insights

Internal consistency between the two modules is what reviewers actually test. If the risk analysis states that a given risk is controlled through a warning in the IFU or on the label, while the corresponding Essential Principles entry is answered as not applicable, the dossier is judged internally inconsistent, and the inconsistency invites questions that are harder to answer than either document alone. The professional solution is to build the risk analysis as a traceable matrix: each row is one hazard, with severity and probability, the control measures, the page reference of the verification evidence, and the residual risk evaluation. The Essential Principles are then mapped item by item onto the same matrix, so that every principle entry points at the hazard row it relates to and every hazard row points at the evidence that closes it. A dossier built this way satisfies both requirements with a single body of work, and the same matrix can be reused directly in later change assessments and in CE or FDA reviews, which multiplies the return on the effort invested. Teams that maintain two separate documents, one for Thailand and one for other markets, typically find that the documents drift apart within one revision cycle, and the drift is precisely what deficiency letters expose.

4. Practical recommendations

• Write the risk analysis against the specific hazards of the product, covering energy hazards, biological hazards, environmental hazards, use errors, and software failures, instead of submitting a generic template.
• Close the loop in five steps: identification, evaluation, control measures, verification of the effectiveness of the controls, and the acceptability determination for residual risk.
• Answer the Essential Principles entry by entry with the method of conformity and an evidence index with document and page numbers, using the table structure shown above.
• Answer non-applicable entries with N/A plus a justification and never leave them blank.
• Reconcile the two modules before submission: every control claimed in the risk analysis must be traceable in test reports, IFU warnings, and label warnings, and the Essential Principles answers must not contradict the risk analysis conclusions.
• On the Abridged route, prepare the intended use statement, the marketing history statement, the safety statement, and the proof of reference authority approval that substitute for the risk analysis exemption.

5. Verification checklist

• □ Verification basis date: 26 October 2026.
• □ Thai FDA website Class 2-4 document list matrix, confirming Risk Analysis and Essential Principles are mandatory on the Full route and the Abridged route exempts the Risk Analysis.
• □ ASEAN CSDT list of Essential Safety and Performance Principles.
• □ ISO 14971 risk management standard.
• □ Thai FDA Abridged route additional declarations: intended use, marketing history, safety statement, and proof of reference authority approval.
• □ Thai FDA reliance route announcement of 2024-06-04, B.E. 2567.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Thailand. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the Thai FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com